We are a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system. We believe T-cell therapy represents a revolutionary step toward providing a potential cure for many forms of cancer, including cancers poorly addressed by current approaches. At Eureka, our mission is to make safe and effective T-cell therapies that are widely accessible to patients as the standard of care for the treatment of multiple hematologic and solid tumors.
The company’s proprietary ARTEMIS™ platform was created to mimic the natural biology of T-cells to fight cancer. Our ARTEMIS™ platform is a novel T-cell therapy construct that is intended to create safer and potentially more effective T-cell therapies than are currently available.
Our proprietary E-ALPHA® antibody discovery platform comprises a highly diverse human-derived antibody phage library of over 100 billion clones with unique antibody sequences and a robust workflow that is designed to enable us to develop highly specific antibodies against target antigens, including peptide-MHC complexes and cell surface proteins.
We are developing a pipeline of novel cancer therapeutics targeting intracellular and cell-surface targets.